---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-305161"
form_type: "8-K"
ticker: "ENGN"
cik: "0001980845"
company_name: "enGene Therapeutics Inc."
filed_at: "2023-12-28T23:59:59+00:00"
generated_at: "2026-06-07T06:37:01.197086+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# enGene enters up to $50M term loan with Hercules Capital; draws $22.5M initially

## Summary
- Up to $50M term loan, initial $22.5M drawn, $8.6M refinances prior debt.
- Interest: prime+0.75% (cap 9.75%) or 9.25% cash, plus 1.15% PIK.
- Maturity Jan 1, 2028; interest-only until July 2025, extendable to Jan 2026 or Jul 2026 if milestones met.
- Warrants to lenders for 2% of principal at $7.21 strike; 62,413 warrants issued initially.
- Negative covenants restrict additional debt, liens, dividends, acquisitions, and IP sales.

## SEC filing metadata
- accession: 0001193125-23-305161
- form_type: 8-K
- ticker: ENGN
- cik: 0001980845
- company_name: enGene Therapeutics Inc.
- filed_at: 2023-12-28T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/0001193125-23-305161-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/d680407d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-305161
- JSON: https://secwatch.observer/filing/0001193125-23-305161.json
- Plain text: https://secwatch.observer/filing/0001193125-23-305161.txt

## Key facts
- Debt Financings
  enGene Therapeutics Inc. amended term loan of up to $50 million with Hercules Capital, Inc. at greater of (a) the prime rate of interest as reported in the Wall Street Journal maturing January 1, 2028.
  - Instrument: term loan
  - Principal: up to $50 million
  - Counterparty: Hercules Capital, Inc.
  - Rate: greater of (a) the prime rate of interest as reported in the Wall Street Journal
  - Maturity: January 1, 2028
  - Event: amendment
  source text: 2021 (the “Prior Loan Agreement”), by, among other things, adding the Company as a co-borrower thereunder. The Amended Loan Agreement provides for a term loan facility of up to $50 million available in multiple tranches (the “Term Loan”), as follows: (i) an initial term loan advance (the “Tranche 1 Advance”) that was made on the Closing Date of $22.5 million,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/0001193125-23-305161-index.htm
- Material Agreements
  enGene Therapeutics Inc. amended Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. valued at up to $50 million (effective 2023-12-22).
  - Action: amendment
  - Agreement: credit facility
  - Counterparty: Hercules Capital, Inc.
  - Value: up to $50 million
  - Effective: 2023-12-22
  source text: On December 22, 2023 (the “Closing Date”), enGene Holdings Inc. (the “Company”), together with its subsidiaries, enGene Inc. and enGene USA, Inc. (collectively with the Company, on a joint and several basis, the “Borrowers”) entered into an Amended and Restated Loan and Security Agreement (the “Amended Loan Agreement”), with Hercules Capital, Inc., as agent and lender (“Hercules” or “the Bank”), and the several banks and other financial institutions or entities from time to time parties thereto (with Hercules, the “Lenders”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1980845/000119312523305161/0001193125-23-305161-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.